Royalty Pharma (RPRX) news
Recent news
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Royalty Pharma (Nasdaq: RPRX) has announced that it will release its third quarter 2026 financial results on Monday, November 4, 2026. The company has not yet provided preliminary details about the performance for the quarter, but investors will be looking closely at key metrics such as revenue,…
AInvest Wire · 4d agoDHL Group - Investment programme running until 2030
DHL Group has announced a multi-year investment programme that will run through 2030, with a focus on strengthening its logistics infrastructure and expanding its presence in key global markets. The initiative includes a EUR 2 billion investment in the Life Sciences & Healthcare (LSH) sector, with…
AInvest Wire · 5d agoRubio: Real opportunities for US pharma, biotech in Iceland
AInvest Wire · 7d agoJagsonpal Pharmaceuticals - Transaction is expected to be completed on or before 01 November, 2026
Jagsonpal Pharmaceuticals has announced that the acquisition of a 69.77% controlling stake in Aequitas Healthcare Private Limited is expected to be finalized on or before 01 November, 2026. This strategic transaction will transition Aequitas into a subsidiary of Jagsonpal, marking inorganic…
AInvest Wire · Sep 23, 2026Nanexa AB - Portfolio includes license agreement with Moderna and undisclosed pharma collaborations
AInvest Wire · Sep 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.